• 1
    Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155167.
  • 2
    Bakker NA, Van Imhoff GW, Verschuuren EA et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327334.
  • 3
    European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): Prevention and treatment. Nephrol Dial Transplant 2002; 17 (Suppl. 4): 3133, 35–36.
  • 4
    Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879888.
  • 5
    Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 10271034; discussion 1035–1036.
  • 6
    Tamai K, Koyama T, Saga T et al. Posttransplant lymphoproliferative disorder in a lung transplant recipient. J Thorac Imaging 2005; 20: 280283.
  • 7
    Marom EM, McAdams HP, Butnor KJ, Coleman RE. Positron emission tomography with fluoro-2-deoxy-D-glucose (FDG-PET) in the staging of post transplant lymphoproliferative disorder in lung transplant recipients. J Thorac Imaging 2004; 19: 7478.
  • 8
    O'Conner AR, Franc BL. FDG PET imaging in the evaluation of post-transplant lymphoproliferative disorder following renal transplantation. Nucl Med Commun 2005; 26: 11071111.
  • 9
    Nalesnik MA. The diverse pathology of post-transplant lymphoproliferative disorders: The importance of a standardized approach. Transpl Infect Dis 2001; 3: 8896.
  • 10
    Green M. ARaPJ. Epstein-Barr virus and lymphoproliferative disorders after transplantation. Am J Transplant 2004; 4 (Suppl. 10): 5965.
  • 11
    Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649655.
  • 12
    Dufour JF, Fey MF. What is the current treatment of PTLD after liver transplantation? J Hepatol 2006; 44: 2326.
  • 13
    Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl. 1):113116.
  • 14
    Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005; 35: 165175.
  • 15
    Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 186196.
  • 16
    Cremerius U, Fabry U, Wildberger JE et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 103111.
  • 17
    Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology 2004; 232: 823829.
  • 18
    Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001; 16: 297304.
  • 19
    Hoffmann M, Kletter K, Diemling M et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10: 11851189.
  • 20
    Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 38753876.